Which place for metformin in the management of type 2 diabetes ?
Abstract
Metformin remains the first-line pharmacological agent for the treatment of type 2 diabetes. This clinical vignette first recalls the fundamental reasons supporting this recommendation. It then considers situations that may raise concerns, particularly in patients with renal disease and those with cardiovascular disease. Finally, several practical advises for a cautious use and an optimization of both tolerance and safety are outlined.
La metformine reste actuellement le premier choix médicamenteux pour le traitement du diabète de type 2. Cette vignette clinique rappelle d’abord les raisons fondamentales justifiant ce choix. Ensuite, elle envisage deux situations qui peuvent poser problème, les patients avec maladie rénale et les patients avec maladie cardiovasculaire. Enfin, quelques précautions sont décrites d’un point de vue pratique pour optimiser la tolérance et la sécurité d’emploi de la metformine.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.